InterCure Ltd. INCR
5.21
(0.05)
(0.95%)
as of 25 Sep
- Market cap
- $62.3M
- P/E
- 9.8×
Follow INCR
| Older periods | Mar '23 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
10.20 | 16.05 | — | — |
P/S ratio |
0.72 | 3.22 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(5.87) | (26.04) | — | — | |
P/B ratio |
0.59 | 2.68 | — | — | |
Price to Tangible BV |
1.29 | 5.81 | — | — | |
EV/Sales |
0.89 | 3.20 | — | — | |
EV/EBITDA |
7.64 | 35.36 | — | — | |
EV/Operating CF |
(422.66) | (1,502.70) | — | — | |
EV/FCF |
(25.91) | (92.12) | — | — | |
Quick Ratio |
1.24 | 1.21 | 1.15 | 1.09 | |
Current Ratio |
1.83 | 1.90 | 1.78 | 1.85 | |
Net Debt/EBITDA |
8.07 | (1.04) | 0.00 | 0.00 | |
Debt/Assets |
22.15% | 12.63% | 9.32% | 15.51% | |
Debt/Equity |
0.37 | 0.20 | 0.15 | 0.27 | |
Asset Turnover |
0.51 | 0.51 | 0.00 | 0.00 | |
Operating CF/Net income |
(245.44) | 0.00 | — | 0.00 | |
Capex/Depreciation |
(0.22) | — | — | (0.38) | |
Interest Coverage |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.14% | 0.10% | — | — | |
Selling, General and Administrative Expense of Revenue |
23.73% | 25.21% | — | — | |
Intangible Assets out of Total Assets |
0.32 | 0.34 | 0.30 | 0.30 | |
Share Based Compensation of Revenue |
1.28% | 0.00% | — | 0.00% | |
Graham Net Nets |
0.24 | 0.06 | — | — | |
Graham Number |
19.73 | 6.15 | — | — | |
Earnings Yield |
9.80% | 6.23% | — | — | |
Free Cash Flow Yield |
(4.78%) | (1.08%) | — | — | |
Revenue per Share |
3.65 | 0.60 | — | — | |
Operating CF per Share |
(1.74) | 0.00 | — | 0.00 | |
Capex per Share |
(0.02) | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(1.76) | 0.00 | — | 0.00 | |
Cash per Share |
3.98 | 0.70 | 0.00 | 0.00 | |
Shareholders Equity per Share |
17.30 | 3.17 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.30 | 3.17 | 0.00 | 0.00 | |
Free Cash Flow |
(15.07) | — | — | 2.50 | |
Working Capital |
54.53 | 51.17 | 43.42 | 48.10 | |
Capital Expenditures |
(0.19) | — | — | (0.91) | |
Net Current Asset Value |
20.76 | 22.01 | 24.68 | 15.23 | |
EV/EBIT |
10.29 | 36.60 | — | — | |
Capex to Sales |
0.01 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.19% | 4.77% | — | — | |
Price to Operating Income |
8.31 | 36.87 | — | — | |
| Other line items | |||||
Average Receivables |
31.71 | 29.32 | 46.37 | 43.29 | |
Average Payables |
27.07 | 26.86 | 25.54 | 31.48 | |
Average Inventory |
33.94 | 34.42 | 37.33 | 40.30 | |
Average Assets |
240.50 | 233.86 | 228.13 | 247.84 | |
Average Common Equity |
149.95 | 147.33 | 137.55 | 138.13 |
Columns are period end dates